·Contact Person: Lindy Kilby (412) 647-2638
·Status: Recruitment completed
A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability and Efficacy of LymphoStat-B Antibody (Monoclonal Anti-BlyS Antibody) in Subjects with Rheumatoid Arthritis (RA)
(lay summary) (physician summary)
·Contact Person: Lindy Kilby (412) 647-2638
·Status: Actively Recruiting
A Multi-Center, Open Label, Continuation Trial of LymphoStat-B Antibody (Monoclonal Anti-BLyS Antibody) in Subjects with Rheumatoid Arthritis (RA) Who Completed the Phase 2 Protocol LBRA01
(lay summary) (physician summary)
·Contact Person: Lindy Kilby (412) 647-2638
·Status: Actively Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group of the Safety and Reduction of Signs and Symptoms During Treatment with MRA Versus Placebo, In Combination with Traditional DMARD Therapy in Patients with Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Current DMARD Therapy (WA18063 and WA18063RG)
(lay summary) (physician summary)
Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies (WA18696)
(lay summary) (physician summary)
·Contact Person: Lindy Kilby (412) 647-2638
·Status: Recruitment completed
A Double Blind, Placebo Controlled, Phase II, Randomized Study of Lovastatin Therapy in the Treatment of Mildly Active Rheumatoid Arthritis
(lay summary) (physician summary)
·Contact Person: Lindy Kilby (412) 647-2638
·Status: Actively Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis and Previously Treated with Biologic Anti-TNFα Agent(s)
(lay summary) (physician summary)
·Contact Person: Lindy Kilby (412) 647-2638
·Status: Actively Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously, in Methotrexate-naïve Subjects with Active Rheumatoid Arthritis
(lay summary) (physician summary)
·Contact Person: Lindy Kilby (412) 647-2638
·Status: Actively Recruiting
SCLERODERMA
National Registry for Childhood Onset Scleroderma
(lay summary)
·Contact Person: Jennifer Jablon (800) 603-8960
·Status: Actively Recruiting
Systemic Sclerosis Twin Study
(lay summary)
·Contact Person: Jennifer Jablon (800) 603-8960
·Status: Actively Recruiting
A randomized, double-blind, placebo-controlled, multicenter study to assess the effect of bosentan on healing and prevention of ischemic digital ulcers in patients with systemic sclerosis (RAPIDS-2 Study)
(lay summary)
·Contact Person: Carol Blair, RN (412) 383-8672
·Status: Recruitment Completed
Long term bosentan open label extension of the RAPIDS-2 study in systemic sclerosis patients with ischemic digital ulcers
(lay summary)
·Contact Person: Carol Blair, RN (412) 383-8672
·Status: Actively Recruiting
SYSTEMIC LUPUS ERYTHEMATOSUS
University of Pittsburgh Lupus Center of Excellence Patient Registry
The purpose of this registry is to identify patients with lupus who are interested in hearing about current and future research studies in which they may be eligible to participate. As a member of the Registry, you will have the opportunity to learn about the Center's research projects on autoimmune disease and participate in those that may interest you and for which you may be eligible.
Molecular Genetics Analysis of Apolipoprotein H in Systemic Lupus Erythematosus.
This study is a collaborative effort between Dr. Ilyas Kamboh, a molecular geneticist, and Dr. Manzi, a clinician/epidemiologist, to examine how APOH genetic variations predict occurrence of antiphospholipid antibodies and thrombotic events in SLE patients.
Complement Receptor-Ligand Assays for Determination of Diagnosis and Disease Activity in Patients with Inflammatory and Immune-Mediated Disorders, and Hematologic Disorders.
(lay summary)
·Contact Person: Margie Ruffing (412) 641-7633
·Status: Actively Recruiting
SLICC: The Systemic Lupus International Collaborationg Clinics Registry for Atherosclerosis in SLE
(lay summary)
·Contact Person: Margie Ruffing (412) 641-7633
·Status: Actively Recruiting
VARIOUS DISEASES
Banking of Biological Samples and Collection of Clinical Data for Connective Tissue Disease Research
(lay summary)
·Contact Person: Mary Lucas (412) 383-8699
·Status: Actively Recruiting
UPMC Arthritis Network Registry
(lay summary)
·Contact Person: Jennifer Jablon (800) 603-8960
·Status: Actively Recruiting
